The company said fiscal 2025 revenue for Q2 (quarter ended March 31) rose 10.3% year over year to $75.5 billion. GAAP diluted EPS was $3.68 (compared with $2.09 in Q2), and adjusted diluted EPS was $4.42 (compared with $3.80 a year earlier).

1. 01

   The company said fiscal 2025 revenue for Q2 (quarter ended March 31) rose 10.3% year over year to $75.5 billion. GAAP diluted EPS was $3.68 (compared with $2.09 in Q2), and adjusted diluted EPS was $4.42 (compared with $3.80 a year earlier).

2. 02

   Cencora said it raised its fiscal 2025 adjusted diluted EPS outlook to $15.70 to $15.95 from the previous range of $15.30 to $15.60.

3. 03

   Cencora said GAAP gross profit for Q2 rose 20.6% year over year to $3.1 billion. It cited higher gross profit in the U.S. Healthcare Solutions segment and larger gains from antitrust litigation settlements as the factors. Those settlement gains were $198.6 million (compared with $8.7 million in Q2).

4. 04

   Cencora said net interest expense for Q2 was $104.0 million, up 62.2% from the prior-year quarter. It cited higher interest expense from the issuance of $1.8 billion of senior notes in December 2024 and a $1.5 billion variable-rate term loan borrowed in January 2025 to finance part of the RCA acquisition.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.